Kirchgesner J, et al. - Researchers scrutinized the risk of serious and opportunistic infections in patients with inflammatory bowel diseases (IBD) treated with thiopurine monotherapy, anti-tumor necrosis factor (TNF) monotherapy, or combination therapy in patients in France. Heterogeneity was discovered in the risks of serious and opportunistic infections among individuals treated with immune-suppressive regimens. Careful consideration of these was recommended and these ought to be weighed against potential benefits for IBD treatment in patient management.